Buy Norditropin Nordiflex 30iu pen
Сontains liquid growth hormone (GH) in a pre-filled multi-dose disposable syringe pen for multiple injections.
The active substance Norditropin Nordiflex – is somatropin, identical to the 191 amino acid sequence of human pituitary growth hormone (GH). Norditropin is produced using recombinant technology and is supplied as a transparent stable sterile solution.
Pharmacodynamics of the use of Norditropin (HGH)
In adults with growth hormone deficiency, somatropin reduces fat mass, increases muscle mass, and also strength, energy and subjective well-being.
Treatment of patients with GH deficiency with somatropin normalizes serum level of IGF-1. The primary and secondary pharmacological effects of somatropin are identical to those of the pituitary GR.
In addition, the following effects have been demonstrated for somatropin:
Stimulation of skeletal muscle growth in patients with GDR, as well as an increase in the number and size of muscle cells
The delay in nitrogen is manifested by a decreased excretion of nitrogen in the urine and a reduced content of urea nitrogen in the serum
In patients, the administration of somatropin leads to the mobilization of lipids, a reduction in body fat reserves and an increase in fatty acids in the plasma
Somatropin induces retention of sodium, potassium and phosphorus in the body.
After therapy with somatropin, the concentrations of inorganic phosphates in serum increase in patients. Somatropin does not significantly affect the level of serum calcium.
Somatropin, replenishing the deficiency of endogenous growth hormone, contributes to the normalization of body structure by increasing muscle mass and reducing body fat.
Most effects of somatropin are realized through insulin-like growth factor I (IGF-I), which is produced in all cells of the body (mainly by liver cells). More than 90% of IGF-I is associated with proteins (GHBP), of which the most important is IRFSB-3.
Somatropin enhances the restructuring of bone tissue, which is manifested by an increase in the activity of biochemical bone markers in plasma. In adults, during the first months of treatment, due to more pronounced bone resorption, a decrease in its mass is observed, however, with continued treatment, the mass of bone tissue increases.
Approximately 80% of somatropin is absorbed after subcutaneous injection, with maximum serum concentrations reaching 3-4 hours.
Dosing and Administration
Norditropin NordiLet is a solution for subcutaneous injection, located in cartridges in a multi-dose, disposable, pre-filled syringe pen, for multiple injections intended for use with NovoFine needles.
The dosage is set by clicking. Norditropin NordiLet allows you to do from 1 to 29 clicks of the dose setting for each injection, which is also followed by a click. The dose of the drug for each click is 0.1333 mg (0.4 IU); The package contains an instruction containing a table of dose transfer (mg) in the appropriate number of clicks.
The dose of the drug is prescribed individually. It is usually recommended to do one subcutaneous injection at night. To prevent the development of lipoatrophy, injection sites should be changed. The procedure for the injection is set out in the instructions for Norditropin NordiLet. Patients should be reminded of the need to wash their hands with soap and / or a disinfectant before using Norditropin NordiLet. Never shake Norditropin NordiLet violently.
Substitution therapy. It is recommended to begin treatment with the use of low doses of the drug: 0.15-0.3 mg / day (which corresponds to 0.45-0.9 IU / day) and gradually increase the dose every month until the dose that is required by a particular patient is achieved.
As a control parameter for titrating the dose, serum level of IGF-I can be used. As the patient’s age increases, the need for growth hormone decreases.
The maintenance dose of the drug is selected individually, but rarely exceeds 1 mg / day (corresponding to 3 IU / day).
Norditropin NordiLet should be protected from exposure to direct sunlight and freezing. Norditropin NordiLet exposed to temperatures below 0 ° C should not be used.
Shelf life before use: 2 years at 2-8 ° C.
After the beginning of application: 28 days at a temperature of 2-8 ° C or 3 weeks at a temperature of no higher than 25 ° C.
There may be fluid retention with the development of peripheral edema. Mostly, adults can have a “tunnel” (carpal tunnel) syndrome. Symptoms, as a rule, are transitory, dose-dependent, may require a dose reduction. In addition, adults can develop joint pain, muscle pain and paresthesia (they are usually short-lived and pass on their own).
Side effects are rare in children. The integrated database contains information on children who received treatment with Norditropin for up to 8 years. The incidence of headaches is 0.04 cases per patient per year.
Antibodies to somatropin are rarely observed with a decrease in its effectiveness.
During the treatment with Norditropin NordiLet, local reactions in the injection area may occur: soreness, numbness, hyperemia, swelling, lipoatrophy, pruritus.
Allergic reactions: skin rash, itching.
Increase in the blood levels of inorganic phosphate, parathyroid hormone and alkaline phosphatase activity.
Acute overdose can lead in the beginning to hypoglycemia and, subsequently, to hyperglycemia. Such fluctuations in glucose concentration were determined only biochemically without clinical manifestations. With prolonged overdose, signs and symptoms characteristic of excess human growth hormone – the development of acromegaly and / or gigantism, as well as the development of hypothyroidism, a decrease in the level of cortisol in the serum may appear. Treatment: withdrawal of the drug, symptomatic therapy.
Concomitant therapy may interfere with the effect of Norditropin NordiLet. The effectiveness of the drug may also be affected by concomitant therapy with other hormones, for example, gonadotropin, anabolic steroids, estrogens and thyroid hormones.
Norditropin NordiLet is supplied ready for use and is a prefilled syringe for multiple injections, consisting of a 1.5 ml cartridge (colorless glass type 1) fixedly fixed in a plastic injector pen. From the bottom, the cartridge is sealed with a plastic stopper in the form of a plunger, and above is a laminated plastic stopper in the form of a disc sealed with an aluminum cover.
Do not use the drug Norditropin NordiLet, if the solution has ceased to be colorless and transparent as water.
You can not use Norditropin NordiLet, if before the first injection you had to do more than 6 idle strokes, in which air is released from the syringe handle.
A specialist in pathology of growth should regularly monitor the condition of children receiving Norditropin NordiLet. The treatment with Norditropin NordiLet should always be started by a doctor who has special knowledge in the field of growth hormone deficiency and its treatment.
During treatment with Norditropin NordiLet, patients with chronic renal failure should be monitored for renal function with a marked decrease or increased glomerular filtration rate (which may indicate hyperfiltration).
The effect of somatropin on carbohydrate metabolism has been established, so patients should also be examined for glucose tolerance impairment.
In patients receiving insulin treatment, with the appointment of the drug Norditropin NordiLet, it may be necessary to adjust its dose.
When treated with Norditropin NordiLet, the serum thyroxine level may decrease due to increased peripheral deiodination of T4 in T3.
Where to buy Norditropin?
You can always buy Northrotropin pen – human growth hormone produced by NovoNordisk in our store, at the best price.
See also: Omnitrope 30IU cartridge